Proactive Investors - Futura Medical PLC (LON:FUM) has announced that its partner, Cooper Consumer Health, has begun pre-launch activities for the launch of MED3000.
Also known as Eroxon, MED3000 is a breakthrough, topical gel formulation for the treatment of erectile dysfunction (ED).
Last May, Futura signed an exclusive licensing agreement with Cooper for the rights to commercialise the product throughout the European Economic Area, the United Kingdom and Switzerland.
Futura's CEO, James Barder, confirmed that Cooper is on track to launch Eroxon in the first half of 2023 and that the first product supplies will be available in the coming months.
MED3000 is set to be the first pan-European topical treatment for ED available without a doctor's prescription, and available over the counter.
If granted marketing authorisation by the US Food and Drug Administration (FDA), MED3000 has the potential to become the first major ED treatment available over-the-counter there too.
Futura has established a network of licensing and distribution partners for the long-term distribution of MED3000 across the globe, including key markets such as the EEA, the UK, Switzerland and South Korea.
The company's corporate advisors are also searching for a US commercial partner, and are engaged in ongoing discussions with potential partners.